These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 11226467)

  • 1. Sepharose-unbinding ricin E as a source for ricin A chain immunotoxin.
    Woo BH; Lee JT; Na DH; Lee KC
    J Immunol Methods; 2001 Mar; 249(1-2):91-8. PubMed ID: 11226467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stability and cytotoxicity of Fab-ricin A immunotoxins prepared with water soluble long chain heterobifunctional crosslinking agents.
    Woo BH; Lee JT; Park MO; Lee KR; Han JW; Park ES; Yoo SD; Lee KC
    Arch Pharm Res; 1999 Oct; 22(5):459-63. PubMed ID: 10549572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capillary electrophoresis to characterize ricin and its subunits with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
    Na DH; Cho CK; Youn YS; Choi Y; Lee KR; Yoo SD; Lee KC
    Toxicon; 2004 Mar; 43(3):329-35. PubMed ID: 15033332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Preparation of SOKT1-RTA immunotoxin and its specific cytotoxic effect on human T lymphocytes].
    Zhong W; Dai B
    Hua Xi Yi Ke Da Xue Xue Bao; 1991 Sep; 22(3):240-4. PubMed ID: 1748404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biodistribution of ricin toxin A chain-monoclonal antibody 791T/36 immunotoxin and influence of hepatic blocking agents.
    Byers VS; Pimm MV; Pawluczyk IZ; Lee HM; Scannon PJ; Baldwin RW
    Cancer Res; 1987 Oct; 47(20):5277-83. PubMed ID: 3498532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of antibody responses to ricin A chain (RTA) by monoclonal anti-RTA antibodies.
    Byers VS; Austin EB; Clegg JA; Denton G; Gunn B; Hooi D; Hudecz F; Price MR; Baldwin RW
    J Clin Immunol; 1993 Nov; 13(6):406-14. PubMed ID: 7507127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ricin A immunotoxins of IgG and Fab of anti-CALLA monoclonal antibody: effect of water soluble long-chain SPDP on conjugate yield, immunoselectivity and cytotoxicity.
    Woo BH; Lee JT; Lee KC
    Arch Pharm Res; 1994 Dec; 17(6):452-7. PubMed ID: 10319157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of ligand effects in intracellular trafficking of ricin A chain using anti-ricin hybridomas.
    Kornfeld SB; Leonard JE; Mullen MD; Taetle R
    Cancer Res; 1991 Mar; 51(6):1689-93. PubMed ID: 1998959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of ricin A chain and ricin A chain-KDEL in Escherichia coli.
    Zhan J; Chen Y; Wang K; Zheng S
    Protein Expr Purif; 2004 Apr; 34(2):197-201. PubMed ID: 15003251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purification of Sepharose-unbinding ricin from castor beans (Ricinus communis) by hydroxyapatite chromatography.
    Woo BH; Lee JT; Lee KC
    Protein Expr Purif; 1998 Jul; 13(2):150-4. PubMed ID: 9675056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
    Dean GS; Pusztai L; Xu FJ; O'Briant K; DeSombre K; Conaway M; Boyer CM; Mendelsohn J; Bast RC
    Clin Cancer Res; 1998 Oct; 4(10):2545-50. PubMed ID: 9796989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibody-ricin A chain conjugates (immunotoxins): potential therapeutic agents for human colon carcinoma.
    Gallagher WJ; Burk MW
    J Surg Res; 1986 Feb; 40(2):159-66. PubMed ID: 3945071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction and characterization of the recombinant immunotoxin RTA-4D5-KDEL targeting HER2/neu-positive cancer cells and locating the endoplasmic reticulum.
    Jiao P; Zhang J; Dong Y; Wei D; Ren Y
    Appl Microbiol Biotechnol; 2018 Nov; 102(22):9585-9594. PubMed ID: 30141083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin.
    Castelletti D; Fracasso G; Righetti S; Tridente G; Schnell R; Engert A; Colombatti M
    Clin Exp Immunol; 2004 May; 136(2):365-72. PubMed ID: 15086403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo enhancement of ricin-A chain immunotoxin activity by novel indolizine calcium channel blockers: delayed intracellular degradation linked to lipidosis induction.
    Jaffrézou JP; Levade T; Thurneyssen O; Chiron M; Bordier C; Attal M; Chatelain P; Laurent G
    Cancer Res; 1992 Mar; 52(5):1352-9. PubMed ID: 1737397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purification and properties of immunotoxins containing one vs. two deglycosylated ricin A chains.
    Ghetie V; Swindell E; Uhr JW; Vitetta ES
    J Immunol Methods; 1993 Nov; 166(1):117-22. PubMed ID: 8228282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotoxins containing A-chain of mistletoe lectin I are more active than immunotoxins with ricin A-chain.
    Tonevitsky AG; Agapov II; Shamshiev AT; Temyakov DE; Pohl P; Kirpichnikov MP
    FEBS Lett; 1996 Aug; 392(2):166-8. PubMed ID: 8772196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells.
    Zhou XX; Ji F; Zhao JL; Cheng LF; Xu CF
    J Gastroenterol Hepatol; 2010 Jul; 25(7):1266-75. PubMed ID: 20594254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction and increase of HLA-DR antigen expression by immune interferon on ML-3 cell line enhances the anti-HLA-DR immunotoxin activity.
    Chiron M; Jaffrezou JP; Carayon P; Bordier C; Roubinet F; Xavier C; Brandely M; Laurent G
    Clin Exp Immunol; 1990 Nov; 82(2):214-20. PubMed ID: 2122930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
    Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
    Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.